Left Ventricular Assist Device (LVAD) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A left ventricular assist device (LVAD) is a surgically implanted, battery-powered mechanical pump that augments the failing left ventricle by continuously drawing blood from the left ventricle and pumping it into the ascending aorta, thereby maintaining adequate cardiac output and systemic blood pressure in patients with advanced heart failure. Modern continuous-flow LVADs — replacing the older pulsatile-flow first-generation devices — use a single moving part (a magnetically levitated rotor) to generate continuous, non-pulsatile blood flow without bearings or valves that can wear, achieving substantially greater durability and reliability. The HeartMate 3 (Abbott) is the current gold-standard device, using full magnetic levitation of the impeller to minimise friction, reduce haemolysis, and virtually eliminate pump thrombosis — the principal failure mode of earlier devices. The system comprises an implanted pump, a percutaneous driveline exiting through the abdominal wall, an external controller that monitors pump function and displays alarms, and rechargeable lithium-ion battery packs worn in a vest or shoulder bag. LVADs are used in two strategic contexts: as a bridge to cardiac transplantation (BTT) in transplant-eligible patients awaiting donor heart availability, or as permanent destination therapy (DT) in patients ineligible for transplantation due to age, comorbidities, or logistical barriers.

LVAD implantation is indicated for patients with advanced (NYHA Class IIIB–IV) systolic heart failure refractory to optimal medical therapy including ACE inhibitors or sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and cardiac resynchronisation therapy when appropriate. Objective criteria include left ventricular ejection fraction (LVEF) below 25%, peak VO₂ below 14 mL/kg/min on cardiopulmonary exercise testing (or below 12 mL/kg/min in patients on beta-blockers), and either transplant candidacy (BTT indication) or defined transplant ineligibility (DT indication). Additional indications include patients with inotrope-dependent advanced heart failure requiring continuous IV inotrope infusion to maintain haemodynamic stability, cardiogenic shock as a bridge to decision or transplant, and selected cases of acute fulminant myocarditis or post-cardiotomy cardiogenic shock. Optimal patient selection is performed by an experienced multidisciplinary heart failure team that evaluates cardiac anatomy (adequate LV dimension for pump inflow cannula placement), right ventricular function (severe RV failure post-implant is a major cause of early mortality), renal and hepatic function (end-organ damage must be recoverable), nutritional status, and psychosocial support for driveline management and device care. Frailty assessment and patient willingness to manage the device long-term are critical factors. Estimated 1-year mortality on LVAD support (LVAD SCORE, HMRS, or MELD-XI risk scores) should be favourable compared with projected mortality without the device.

LVAD implantation is performed under general anaesthesia via median sternotomy with cardiopulmonary bypass (CPB). Before initiating CPB, the ascending aorta and right atrium are cannulated for CPB circuit connection. The pericardium is opened to expose the cardiac apex and ascending aorta. The pump inflow cannula — a titanium conduit 25–28 mm in diameter — is secured into the left ventricular apex using a circular sewing ring sutured to the ventricular myocardium; a coring knife removes a cylinder of LV apex muscle, creating the inflow orifice. The outflow graft — a 14 mm Dacron graft — is sewn end-to-side onto the ascending aorta and connected to the pump outflow port. The driveline — carrying power cables from the implanted pump — is tunnelled through the abdominal wall to a designated exit site on the right or left upper quadrant of the abdomen, emerging percutaneously. The pump is positioned in the pericardial cavity or pre-peritoneal space. After de-airing the circuit, CPB is weaned as the LVAD begins generating flow at 6,000–9,000 revolutions per minute (RPM in HeartMate 3), supplementing native cardiac output to achieve haemodynamic goals. Transoesophageal echocardiography guides septal position optimisation and confirms adequate pump filling throughout the procedure. Median sternotomy is closed with sternal wires and layered sutures. Operating time is 4–6 hours.

The MOMENTUM 3 randomised controlled trial — the pivotal study establishing HeartMate 3 superiority over HeartMate II — demonstrated 79% survival at 2 years with LVAD support, with significantly lower rates of disabling stroke (6.1% vs 12.3% with HeartMate II) and pump thrombosis (requiring emergency exchange), representing a transformative advance in LVAD safety. Quality of life improves dramatically after LVAD implantation: NYHA functional class improves from IV to II–III in most patients, 6-minute walk distance increases by 100–150 metres within 3–6 months, and patient-reported outcomes including fatigue, breathlessness, and depression significantly improve. In patients ineligible for transplantation, LVADs offer survival advantages over medical management: the REMATCH trial (the landmark early trial) demonstrated 52% relative risk reduction in mortality at 1 year versus optimal medical therapy. Haemodynamic stabilisation achieved by LVAD — restoration of normal end-organ perfusion pressure — also reverses hepatic and renal dysfunction in many patients who are bridged to transplant or destination therapy, allowing them to eventually qualify for transplant listing. Destination therapy LVADs are now considered an acceptable therapeutic option offering survival and quality-of-life benefits comparable to cardiac transplantation in carefully selected patients over 65 years ineligible for transplant.

LVAD implantation carries significant early and late risks that require careful patient selection and ongoing monitoring. Operative mortality within 30 days is 5–10% at experienced LVAD centres. Right heart failure after LVAD implantation — the right ventricle losing its preload reserve as the LVAD increases venous return — is the principal early complication, affecting 20–30% of patients and requiring temporary right ventricular mechanical support (RVAD) in 5–10%. Driveline infection — bacterial contamination of the percutaneous driveline exit site — is the most persistent long-term complication, affecting 20–30% of patients over 2 years despite meticulous wound care and antibiotic prophylaxis; deep infections extending to the pump pocket are life-threatening and difficult to eradicate without device exchange. Stroke affects 10–15% of patients annually — the dominant cause of device-related morbidity and mortality — and is reduced by maintaining INR in the therapeutic range (2.0–3.0 for HeartMate 3) and by the HeartMate 3's haemocompatibility design features. Gastrointestinal bleeding — from arteriovenous malformations in the bowel related to the loss of pulsatility and acquired von Willebrand factor deficiency from shear stress — affects 18–30% of patients on continuous-flow LVAD support. Device malfunction requiring pump exchange or hospitalisation occurs in approximately 3–5% annually with modern continuous-flow LVADs. Patients must never disconnect the driveline without medical supervision; battery failure without rapid backup causes haemodynamic collapse.

Intensive care unit (ICU) stay averages 7–14 days for uncomplicated LVAD implantation — covering the highest-risk period for right heart failure, bleeding, and arrhythmia. Step-down to a monitored ward follows as haemodynamic stability is confirmed. Total hospitalisation is 2–4 weeks. Before discharge, patients and their designated carers must complete LVAD training: driveline exit site care (daily wound cleaning, dressing application, securing of the driveline to prevent traction trauma — the leading cause of site infection), controller operation (responding to alarms, switching between power sources), battery management (charging schedule, carrying spare batteries at all times), and emergency protocols (what to do if the controller alarms, power failure, or the patient collapses). Anticoagulation with warfarin (INR 2.0–3.0) and aspirin (81–100 mg daily) is maintained lifelong, with frequent INR monitoring. Cardiac rehabilitation begins at 4–6 weeks post-discharge with progressive aerobic exercise under supervision. Activity restrictions are gradually lifted: light activities from 4–6 weeks, swimming and contact sports are permanently contraindicated (waterproofing the driveline exit site is possible for showering with waterproof coverings but immersion carries infection risk). Patients carry an emergency LVAD device identification card and inform emergency services of the implanted device. Outpatient LVAD clinic follow-up occurs every 1–3 months: pump parameters, INR, haematology, renal function, echocardiography, and driveline site assessment are reviewed at each visit.